Written Communication Relating to an Issuer or Third Party (sc To-c)
January 23 2018 - 5:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of
the Securities Exchange Act of 1934
Bioverativ Inc
(Name of Subject Company)
BLINK
ACQUISITION CORP.
SANOFI-AVENTIS NA HOLDING, INC.
SANOFI-AVENTIS AMERIQUE DU NORD SAS
SANOFI
(Names of Filing
Persons Offerors)
Common Stock, Par Value $0.001 Per Share
(Title of Class of Securities)
09075E100
(Cusip Number of Class of Securities)
Karen Linehan
Executive
Vice President Legal Affairs and General Counsel
Sanofi
54, Rue La Boétie, 75008
Paris, France
Telephone:
011 + 33 1 53 77 40 00
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications on Behalf of Filing Persons)
Copies to:
Michael J. Aiello, Esq.
Sachin Kohli, Esq.
Weil,
Gotshal & Manges LLP
767 Fifth Avenue
New York, NY 10153
(212)
310-8000
CALCULATION OF
FILING FEE
|
|
|
|
Transaction Valuation*
|
|
Amount of Filing Fee*
|
N/A
|
|
N/A
|
|
|
*
|
A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.
|
☐
|
Check box if any part of the fee is offset as provided by Rule
0-11(a)(2)
and identify the filing with which the offsetting fee was previously paid. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount Previously Paid:
|
|
Not applicable.
|
|
|
|
|
|
Filing Party:
|
|
Not applicable.
|
|
|
|
|
Form or Registration No.:
|
|
Not applicable.
|
|
|
|
|
|
Date Filed:
|
|
Not applicable.
|
|
|
|
|
☑
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
☑
|
third-party tender offer subject to Rule
14d-1.
|
☐
|
issuer tender offer subject to Rule
13e-4.
|
☐
|
going-private transaction subject to Rule
13e-3.
|
☐
|
amendment to Schedule 13D under Rule
13d-2.
|
Check the following box if
the filing is a final amendment reporting the results of the tender offer. ☐
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Transcript of investor call on January 22, 2018.
|
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Jul 2023 to Jul 2024